Codiak Stock Analysis

CDAK -  USA Stock  

USD 24.13  0.92  3.67%

The recent price surge of Codiak Biosciences could raise concerns from traders as the firm it trading at a share price of 24.13 on 134,000 in volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.94. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Codiak Biosciences partners.
Continue to Trending Equities.

Search Stock Analysis 

The Codiak Biosciences stock analysis report makes it easy to digest most publicly released information about Codiak Biosciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Codiak stock analysis module also helps to analyze the Codiak Biosciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Codiak Stock Analysis Notes

The company had not issued any dividends in recent years. Codiak BioSciences, Inc. is harnessing exosomesnatural intercellular messengersto pioneer a new class of biologic medicines, exosome therapeutics. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts. CDAK New operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 101 people. For more info on Codiak Biosciences please contact the company at 617 949 4100 or go to

Codiak Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Codiak Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Codiak Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Codiak Biosciences is way too risky over 90 days horizon
Codiak Biosciences appears to be risky and price may revert if volatility continues
Codiak Biosciences has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 622 K. Net Loss for the year was (94.46 M) with loss before overhead, payroll, taxes, and interest of (59.11 M).
Codiak Biosciences currently holds about 50.95 M in cash with (43.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.88.
Latest headline from Codiak Biosciences Inc falls -5.8710 percent for June 15 -

Codiak Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Codiak Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Codiak Biosciences backward and forwards among themselves. Codiak Biosciences' institutional investor refers to the entity that pools money to purchase Codiak Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares3.3 M48.3 M
Flagship Pioneering IncCommon Shares2.6 M39.3 M
Boxer Capital LlcCommon SharesM15.5 M
University Of Texastexas Am Investment Managment CoCommon Shares847.1 K12.8 M
Ensign Peak Advisors IncCommon Shares650.5 K9.8 M
Franklin Resources IncCommon Shares608.5 K9.2 M
Oracle Investment Management IncCommon Shares545.4 K8.2 M
Note, although Codiak Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Codiak Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 224.8 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Codiak Biosciences's market, we take the total number of its shares issued and multiply it by Codiak Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

Codiak Biosciences management efficiency ratios could be used to measure how well codiak biosciences manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 19th of June, Codiak Biosciences shows the mean deviation of 4.58, and Risk Adjusted Performance of 0.0904. Codiak Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Codiak Biosciences, which can be compared to its rivals. Please confirm Codiak Biosciences downside deviation, treynor ratio, expected short fall, as well as the relationship between the variance and potential upside to decide if Codiak Biosciences is priced correctly, providing market reflects its regular price of 24.13 per share. Given that Codiak Biosciences has jensen alpha of 0.7379, we suggest you to validate Codiak Biosciences's prevailing market performance to make sure the company can sustain itself at a future point.

Codiak Biosciences Price Movement Analysis

The output start index for this execution was thirty-nine with a total number of output elements of twenty-two. Codiak Biosciences Triple Exponential Moving Average indicator shows smoothing effect of Codiak Biosciences price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average. View also all equity analysis or get more info about triple exponential moving average overlap studies indicator.

Codiak Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Codiak Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Codiak Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Codiak Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eggimann Annevirginie over three weeks ago via Macroaxis 
Acquisition by Eggimann Annevirginie of 20000 shares of Codiak Biosciences subject to Rule 16b-3
Wheler Jennifer J over a month ago via Macroaxis 
Acquisition by Wheler Jennifer J of 100000 shares of Codiak Biosciences subject to Rule 16b-3
Melas Kyriazi Theo over a month ago via Macroaxis 
Purchase by Melas Kyriazi Theo of 6600 shares of Codiak Biosciences
Morrison Briggs over three months ago via Macroaxis 
Purchase by Morrison Briggs of 4761 shares of Codiak Biosciences
Sorensen Benny over three months ago via Macroaxis 
Acquisition by Sorensen Benny of 31000 shares of Codiak Biosciences subject to Rule 16b-3
Howze Yalonda over six months ago via Macroaxis 
Acquisition by Howze Yalonda of 41576 shares of Codiak Biosciences subject to Rule 16b-3
Arch Venture Fund Viii Lp over six months ago via Macroaxis 
Codiak Biosciences exotic insider transaction detected
Alaska Permanent Fund Corp over six months ago via Macroaxis 
Conversion by Alaska Permanent Fund Corp of 1320097 shares of Codiak Biosciences
Flagship Ventures Fund V General Partner Llc over six months ago via Macroaxis 
Conversion by Flagship Ventures Fund V General Partner Llc of 660048 shares of Codiak Biosciences
Arch Venture Fund Viii Lp over six months ago via Macroaxis 
Conversion by Arch Venture Fund Viii Lp of 1784572 shares of Codiak Biosciences
Sorensen Benny over six months ago via Macroaxis 
Codiak Biosciences exotic insider transaction detected
Verma Ajay over six months ago via Macroaxis 
Codiak Biosciences exotic insider transaction detected

Codiak Biosciences Predictive Daily Indicators

Codiak Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Codiak Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Codiak Biosciences Forecast Models

Codiak Biosciences time-series forecasting models is one of many Codiak Biosciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Codiak Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Codiak Biosciences Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Codiak Biosciences stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Codiak shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Codiak Biosciences. By using and applying Codiak Stock analysis, traders can create a robust methodology for identifying Codiak entry and exit points for their positions.
Codiak BioSciences, Inc. is harnessing exosomesnatural intercellular messengersto pioneer a new class of biologic medicines, exosome therapeutics. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts. CDAK New operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Codiak Biosciences to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Positions Ratings Now


Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module
Continue to Trending Equities. Note that the Codiak Biosciences information on this page should be used as a complementary analysis to other Codiak Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Codiak Biosciences Stock analysis

When running Codiak Biosciences price analysis, check to measure Codiak Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Codiak Biosciences is operating at the current time. Most of Codiak Biosciences' value examination focuses on studying past and present price action to predict the probability of Codiak Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Codiak Biosciences' price. Additionally, you may evaluate how the addition of Codiak Biosciences to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
The market value of Codiak Biosciences is measured differently than its book value, which is the value of Codiak that is recorded on the company's balance sheet. Investors also form their own opinion of Codiak Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Codiak Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Codiak Biosciences' market value can be influenced by many factors that don't directly affect Codiak Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Codiak Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Codiak Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Codiak Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.